Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying

Published 19/01/2023, 14:04
Updated 19/01/2023, 15:10
© Reuters.  Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying

© Reuters. Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying

Benzinga - The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Enzo Biochem

  • The Trade: Enzo Biochem, Inc. (NYSE: ENZ) 10% owner James G Wolf bought a total of 303,000 shares at an average price of $2.47. To acquire these shares, it cost around $749.4 thousand.
  • What’s Happening: Enzo Biochem has been granted U.S. patent number 11,554,111 Titled "Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection."
  • What Enzo Biochem Does: Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally.

Xos

  • The Trade: Xos, Inc. (NASDAQ: XOS) Director George N Mattson acquired a total of 128,666 shares at an average price of $0.98. The insider spent around $126.38 thousand to buy those shares.
  • What’s Happening: The company’s stock jumped 69% over the past month.
  • What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
Check This Out: Top Real Estate Stocks That May Rally

Myomo

  • The Trade: Myomo, Inc. (NYSE: MYO) CEO Paul R Gudonis acquired a total of 307,692 shares at an average price of $0.33. To acquire these shares, it cost around $100 thousand.
  • What’s Happening: Myomo recently priced its $6.5 million public offering at $0.325 per share.
  • What Myomo Does: Myomo Inc is a medical robotics company. It develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders.
Don’t forget to check out our premarket coverage here

Context Therapeutics

  • The Trade: Context Therapeutics Inc. (NASDAQ: CNTX) CEO Martin Lehr acquired a total of 6,783 shares at an average price of $0.74. The insider spent $5 thousand to buy those shares.
  • What’s Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
  • What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.